Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005810 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

A Phase 2 study of Prostate Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
7
Study locations

NCT00005810 is a Phase 2 study of Prostate Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005810, a Phase 2 study of Prostate Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
7
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG carboplatin
  • DRUG docetaxel
  • BIOLOGICAL filgrastim
  • DRUG estramustine phosphate sodium

Study Locations (7)

California

  • UCSF Cancer Center and Cancer Research Institute - San Francisco

Illinois

  • University of Chicago Cancer Research Center - Chicago

Maryland

  • Marlene & Stewart Greenebaum Cancer Center, University of Maryland - Baltimore

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New Hampshire

  • Norris Cotton Cancer Center - Lebanon

New York

  • Memorial Sloan-Kettering Cancer Center - New York

North Carolina

  • Lineberger Comprehensive Cancer Center, UNC - Chapel Hill

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2000-03
Est. Completion 2006-06
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005810

The ClinicalTrials.gov registry entry for NCT00005810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.

NCT00005810 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Maryland.

Frequently Asked Questions

What is clinical trial NCT00005810 about?

NCT00005810 is a clinical study titled "Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...

What is the current status of trial NCT00005810?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2000-03. Estimated completion is 2006-06.

What conditions does trial NCT00005810 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00005810?

The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), filgrastim (BIOLOGICAL), estramustine phosphate sodium (DRUG).

Who is sponsoring clinical trial NCT00005810?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005810 being conducted?

This trial has 7 study locations across California, Illinois, Maryland, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.